The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum.
about
Cannabinoids in health and diseaseCiliary neurotrophic factor protects striatal neurons against excitotoxicity by enhancing glial glutamate uptake.The endocannabinoid system as a target for the treatment of neurodegenerative disease.Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice.Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.The therapeutic potential of cannabinoids for movement disorders.Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotectionSativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.Cannabinoid modulation of neuroinflammatory disorders.Interactions between CB(1) receptors and TRPV1 channels mediated by 12-HPETE are cytotoxic to mesencephalic dopaminergic neurons.Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease.The endocannabinoid system as a target for the treatment of motor dysfunction.The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG.Effects of opioids, cannabinoids, and vanilloids on body temperature.The endocannabinoid system as a target for the treatment of neuronal damage.Prospects for cannabinoid therapies in basal ganglia disorders.Cannabinoids, multiple sclerosis and neuroprotection.Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications.Cannabinoids: Glutamatergic Transmission and Kynurenines.Endocannabinoid system in neurodegenerative disorders.Cannabinoids for the Treatment of Movement Disorders.Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington's Disease.Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease.The bright side of psychoactive substances: cannabinoid-based drugs in motor diseases.The cannabinoid CB1 receptor biphasically modulates motor activity and regulates dopamine and glutamate release region dependently.Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease.Striatal adenosine-cannabinoid receptor interactions in rats over-expressing adenosine A2A receptors.
P2860
Q24633884-E5E30824-31AB-4062-B379-9461F29499CCQ33559739-A9951C0E-CA1F-419F-90B0-3B20A1AD6D54Q34098196-AFAE73AB-07E3-48A6-839F-AA309F7C6C39Q34440282-A449D012-1D23-4C5D-8B2F-B9FBBBB8E829Q34617484-E6288065-E203-4563-ABEC-746B3A7FAF4DQ35171113-37836423-A055-4927-B88E-2857C9F523A7Q35499568-BDA44725-BBD1-46DB-AA4C-0DE1CA714889Q36056302-B429DE2A-B1FE-4612-82B8-685F1A2BC891Q36067324-25C40E09-4A47-49BD-AD66-3155C72CB448Q36882571-64C9CE1C-B0D3-4B77-871D-C07B9B220494Q37253331-369CFE1C-FF1B-4B11-80B8-7004486C2EABQ37394164-F74851EA-8566-4377-98BC-3B52C88B68A6Q37577451-B5E80647-D053-40D8-B70D-90C61E415104Q37692352-F11A477E-666B-4A64-B606-D17E526A548CQ37709370-D2020649-749C-4D57-BED3-A4FA2C7135A3Q37872326-54E94D58-FE29-4074-9DEB-2DC5ADD2BF4AQ37960199-8F3B2809-0313-4802-A9A2-78433E8D213AQ38563981-D3842012-2C2B-4CEA-BD10-E4651D4CE6C7Q38819251-674A09C4-5ABE-49DD-8875-2B433FFAFA7DQ39368845-B5986A8F-1400-4230-AB2C-97DFC11A6B90Q40701861-4FE02E80-0A10-4B35-B6AE-40FEEB2445F2Q42289980-15545CBA-22B0-4926-88A2-2E84D95C1290Q42478056-E3A1B93A-D656-4960-993D-8FE98B64C6EAQ42495608-C96B042B-BA4F-4D87-8BC7-F61D6FC05BE5Q45174910-15892242-D0A7-4351-8BAE-4B2736AB337BQ45303268-BC6ABA89-BF56-4C44-BC7B-F3AF895DDDC0Q50917064-5D73D276-35D3-474F-96EB-147455E91E9B
P2860
The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
The cannabinoid receptor agoni ...... inic acid in the rat striatum.
@en
The cannabinoid receptor agoni ...... inic acid in the rat striatum.
@nl
type
label
The cannabinoid receptor agoni ...... inic acid in the rat striatum.
@en
The cannabinoid receptor agoni ...... inic acid in the rat striatum.
@nl
prefLabel
The cannabinoid receptor agoni ...... inic acid in the rat striatum.
@en
The cannabinoid receptor agoni ...... inic acid in the rat striatum.
@nl
P2093
P50
P921
P1433
P1476
The cannabinoid receptor agoni ...... linic acid in the rat striatum
@en
P2093
D Piomelli
M Galluzzo
M T Tebano
P304
P356
10.1016/J.NEUROPHARM.2006.06.013
P577
2006-08-08T00:00:00Z